Clinical Drug Investigation

, Volume 22, Issue 5, pp 321–327 | Cite as

Effects of a Low Dose of Oral Ademetionine (SAMe) on Behaviour and Quality of Life in Elderly Patients with Mild Mood Disorders

  • Paolo Pancheri
Original Research Article

Abstract

Objective

Ademetionine (SAMe) is a naturally occurring substance with proven antidepressant activity. This study assessed the effects of a low dose of ademetionine on behaviour and quality of life in elderly patients with mild mood disorders.

Design and study participants

In this open-label study, 198 elderly outpatients who approached their general practitioners reporting a nonspecific mood deterioration received oral ademetionine l00mg twice daily for 2 months. Patients’ response to treatment was assessed using a Behavioural and Quality Of Life (BQOL) self-assessment questionnaire and a Patient Evaluation of Therapy questionnaire.

Results

Ademetionine significantly improved behaviour and quality of life over the 2-month treatment period (p < 0.001 vs baseline). Treatment compliance was high (97.3%) and no serious adverse events were reported.

Conclusions

Oral ademetionine l00mg twice daily is well tolerated and may improve behaviour and quality of life in elderly patients with mild mood disorders.

Keywords

Hamilton Depression Rate Scale Score Endogenous Depression Tolerability Score Adenosyl Methionine Adenosyl Transferase 

Notes

Acknowledgements

This study was supported by a grant from BioResearch SA, San Antonino, Switzerland, which also provided the study medication.

The following investigators participated in the study: R. Bardelli, Balerna, Switzerland; S. Bernasconi Coduri, Mendrisio, Switzerland; P. Bettelini-Lura, Riva S. Vitale, Switzerland; L. Binaghi, Coldrerio, Switzerland; M. Casartelli, Balerna, Switzerland; G. Ceracchini, Chiasso, Switzerland; R. Di Stefano, Pregassona, Switzerland; C. Folatti, Massagno, Switzerland; F. Fransioli, Airolo, Switzerland; G. Frey, Breganzona, Switzerland; M.E. Fritz, Castel S. Pietro, Switzerland; B. Galli, Losone, Switzerland; L. Genini, Paradiso, Switzerland; L. Heitmann, Chiasso, Switzerland; V. Manzocchi, Arzo, Switzerland; C. Poloni, Lugano, Switzerland; N. Realini, Chiasso, Switzerland; A. Rusca, Arzo, Switzerland. The author thanks Carlo Di Padova and Gabrielle Boissard for critical input, and Giovanna Bagnasco for editorial assistance.

References

  1. 1.
    Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989; 38: 389–416PubMedCrossRefGoogle Scholar
  2. 2.
    Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opin Invest Drugs 1997; 6:417–26Google Scholar
  3. 3.
    Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987; 83(Suppl 5A): 95–103PubMedCrossRefGoogle Scholar
  4. 4.
    Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980; 209: 1082–90PubMedCrossRefGoogle Scholar
  5. 5.
    Consogno E, Racagni G, Popoli M, et al. Long-term treatment with S-adenosylmethionine induces changes in presynaptic CAM II kinase and synapsin I. Biol Psychiatry 2001; 50: 337–44PubMedCrossRefGoogle Scholar
  6. 6.
    Cimino M, Vantini G, Algeri S, et al. Age-related modification of dopaminergic and beta-adrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 1984; 34: 2029–39PubMedCrossRefGoogle Scholar
  7. 7.
    Bottiglieri T, Carney MWP, Edeh J. A biochemical study of depressed patients receiving S-adenosyl-1-methionine (SAM). In: Borchardt RT, Creveking CR, Ueland PM, editors. Biological methylation and drug design. Clifton (NJ): Humana Press, 1986: 327–38CrossRefGoogle Scholar
  8. 8.
    Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand Suppl 1994; 154: 19–26PubMedCrossRefGoogle Scholar
  9. 9.
    Fonlupt P, Rey C, Pacheco H. Phospholipid methylation and noradrenaline exchanges in a synaptosomal preparation from the rat brain. J Neurochem 1982; 38: 1615–20PubMedCrossRefGoogle Scholar
  10. 10.
    Zanotti S, Mori S, Radaelli R, et al. Modifications in brain cAMP and calcium/calmodulin-dependent protein kinases induced by treatment with S-adenosylmethionine. Neuropharmacology 1998;37: 1081–9PubMedCrossRefGoogle Scholar
  11. 11.
    Reynolds EH, Carney MWP, Toone BK. Methylation and mood. Lancet 1984; 2: 196–8PubMedCrossRefGoogle Scholar
  12. 12.
    Reynolds EH, Stramentinoli G. Folic acid, S-adenosyl-1-methionine and affective disorder. Psychol Med 1983; 13: 705–10PubMedCrossRefGoogle Scholar
  13. 13.
    Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid Sadenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990; 53: 1096–8PubMedCrossRefGoogle Scholar
  14. 14.
    Fazio C, Andreoli V, Agnoli A, et al. Effeti terapeutici e meccanismo d’azione della S-adenosil-1-methionina (SAM) nelle sindromi depressive. Minerva Med 1973; 64: 1515–29PubMedGoogle Scholar
  15. 15.
    Benelli A, Filaferro M, Bertolini A, et al. Influence of S-adenosyl-L-methionine on chronic mild stress-induced anhedonia in castrated rats. Br J Pharmacol 1999; 127: 645–54PubMedCrossRefGoogle Scholar
  16. 16.
    Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984; 141: 448–50PubMedGoogle Scholar
  17. 17.
    Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-L-methionine. Acta Psychiatr Scand 1990; 81: 432–6PubMedCrossRefGoogle Scholar
  18. 18.
    Kagan BL, Rosenlicht N, Gerner RH. Oral S-Adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990; 147: 591–5PubMedGoogle Scholar
  19. 19.
    Agnoli A, Andreoli V, Casacchia M, et al. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 1976; 13: 43–54PubMedCrossRefGoogle Scholar
  20. 20.
    Caruso I, Fumagalli M, Bocassini L, et al. Treatment of depression in rheumatoid arthritic subjects: a comparison of S-adenosyl-methionine (Samyr) and placebo in a double blind study. Clin Trials J 1987; 24: 305–10Google Scholar
  21. 21.
    Bell KM, Plon L, Bunney WE, et al. SAMe treatment of depression: a controlled clinical trial. Am J Psychiatry 1988; 145: 1110–4PubMedGoogle Scholar
  22. 22.
    Carney MWP. Neuropharmacology of S-adenosylmethionine. Clin Neuropharmacol 1986; 9: 235–43PubMedCrossRefGoogle Scholar
  23. 23.
    Pancheri P, Racagni G, Delle Chiaie R, et al. Recent experimental and clinical findings on the efficacy and safety of ademetionine in the pharmacological treatment of depression. G Ital Psicopatol 1997; 3: 1–23Google Scholar
  24. 24.
    Lyness JM, King DA, Cox C, et al. The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disability. J Am Geriatr Soc 1999; 47: 647–52PubMedGoogle Scholar
  25. 25.
    Geiselmann B, Bauer M. Subthreshold depression in the elderly: qualitative or quantitative distinction? Compr Psychiatry 2000; 41: 2 (Suppl 1): 32-8CrossRefGoogle Scholar
  26. 26.
    American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. American Psychiatric Association: Washington, DC, 1994Google Scholar
  27. 27.
    Beck DA, Koenig HG. Minor depression: a review of the literature. Int J Psychiatry Med 1996; 26: 177–209PubMedCrossRefGoogle Scholar
  28. 28.
    Szegedi A, Wetzel H, Angersbach D, et al. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline. J Affect Disord 1997; 45: 167–78PubMedCrossRefGoogle Scholar
  29. 29.
    Miller CA, Hooper CL, Bakish D. A comparison of placebo response with major depressive disorder in patients recruited through newspaper advertising versus consultation referrals. Psychopharmacol Bull 1997; 33: 647–51PubMedGoogle Scholar
  30. 30.
    Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55: 334–43PubMedCrossRefGoogle Scholar
  31. 31.
    Fava M, Rosenbaum JF. Transmethylation and the central nervous system. Acta Neurol Scand 1994; 89Suppl 154: 1–41Google Scholar
  32. 32.
    Bottiglieri T, Chary TK, Laundy M, et al. Transmethylation in depression. Ala J Med Sci 1988; 25: 296–301PubMedGoogle Scholar
  33. 33.
    Fava M, Rosenbaum JF, MacLaughlin R, et al. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr Res 1990; 24: 177–84PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2002

Authors and Affiliations

  • Paolo Pancheri
    • 1
  1. 1.III Clinica PsichiatricaUniversità di Roma ‘La Sapienza’RomaItaly

Personalised recommendations